Is a recent venous thromboembolism a contraindication to oral medroxyprogesterone acetate (MPA)?

Yes, recent VTE is an absolute contraindication to oral medroxyprogesterone acetate (MPA).

Women with a personal history of venous thromboembolism should not use oral medroxyprogesterone acetate due to documented increased VTE risk with this specific progestogen. The FDA label explicitly lists "active thrombophlebitis, or current or past history of thromboembolic disorders" as contraindications to medroxyprogesterone acetate 1.

Evidence-Based Reasoning

Why MPA is Different from Other Progestogens

While most progestin-only contraceptives are considered safe for women with VTE history, medroxyprogesterone acetate is the notable exception. Multiple guidelines and studies specifically identify MPA as problematic:

• The 2018 French guidelines state that "progestin-only contraceptives are not associated with vascular risk (arterial or venous) outside of medroxyprogesterone acetate" 2
• The 2012 French Society of Endocrinology guidelines note that "two studies of the link between medroxyprogesterone acetate and the risk of venous thrombosis call for caution," with one WHO study showing a non-significant trend (OR: 2.19) and another showing a significant increase in VTE risk 3
• A 2022 U.S. study found oral medroxyprogesterone acetate significantly associated with increased VTE odds (aOR 1.98,99% CI 1.41-2.80), and depot medroxyprogesterone acetate even more so (aOR 2.37,99% CI 1.95-2.88) 4

The Pharmacological Explanation

The increased risk is attributed to MPA's unique pharmacological properties when used at high doses 3. Unlike low-dose progestins that don't affect hemostatic parameters, MPA appears to have prothrombotic effects.

Clinical Algorithm for Women with Recent VTE

For women with personal history of VTE requiring contraception:

1. First-line options (safe progestin-only methods):

   • Levonorgestrel IUD
   • Etonogestrel implant
   • Low-dose oral norethindrone
   • Oral desogestrel 75 mcg
   • Oral progesterone

2. Absolute contraindications:

   • All combined hormonal contraceptives (estrogen-containing)
   • Oral medroxyprogesterone acetate
   • Depot medroxyprogesterone acetate

3. Non-hormonal alternative:

   • Copper IUD (preferred by some guidelines as first choice) 3

Critical Timing Consideration

The French guidelines specify that in the acute phase of VTE, all hormonal contraception should be discontinued and replaced with barrier methods, with access to emergency contraception 3. Only after the acute phase can safe progestin-only options be considered.

Common Pitfall to Avoid

Do not assume all progestin-only contraceptives are equivalent for VTE risk. While the 2024 CDC guidelines show DMPA can be initiated anytime without examination 5, this does not override the specific VTE contraindication. The pharmacological properties of medroxyprogesterone acetate distinguish it from other progestins, making it uniquely problematic in women with thrombotic history.

The evidence consistently demonstrates that while most progestin-only methods are safe alternatives for women with VTE history, medroxyprogesterone acetate—whether oral or depot formulation—carries documented increased risk and should be avoided 2, 6, 4.